Mia Shepherdson

Dr. Mia Shepherdson

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KMKay Khine Myo Min
Kay Khine Myo Min
CFCharlie Ffrench
Charlie Ffrench
CJClaire F. Jessup
Claire F. Jessup
MSMia Shepherdson
Mia Shepherdson
Savio George BarretoSavio George Barreto
Savio George Barreto
Claudine BonderClaudine Bonder
Claudine Bonder
An overabundance of desmoplasia in the tumour microenvironment (TME) is one of the defining features that influences pancreatic ductal adenocarcinoma (PDAC) development, progression, metastasis, and treatment resistance. Desmoplasia is characterised by the recruitment and activation of fibroblasts, heightened extracellular matrix deposition (ECM) and reduced blood supply, as well as increased inflammation through an influx of inflammatory cells and cytokines, creating an intrinsically immunosuppressive TME with low immunogenic potential. Herein, we review the development of PDAC, the drivers that initiate and/or sustain the progression of the disease and the complex and interwoven nature of the cellular and acellular components that come together to make PDAC one of the most aggressive and difficult to treat cancers. We review the challenges in delivering drugs into the fortress of PDAC tumours in concentrations that are therapeutic due to the presence of a highly fibrotic and immunosuppressive TME. Taken together, we present further support for continued/renewed efforts focusing on aspects of the extremely dense and complex TME of PDAC to improve the efficacy of therapy for better patient outcomes.

10 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MSMia Shepherdson
Mia Shepherdson
SLShalem Leemaqz
Shalem Leemaqz
GSGurmeet Rajinder Singh
Gurmeet Rajinder Singh
CRCourtney Ryder
Courtney Ryder
SUShahid Ullah
Shahid Ullah
Savio George BarretoSavio George Barreto
Savio George Barreto
Background and Aims: A concerning rise in incidence of young-onset cancers globally led to the examination of trends in incidence and survival of gastrointestinal (GI) adenocarcinomas in the Northern Territory (NT), Australia, over a 28-year period, with a special emphasis on Indigenous peoples. Methods: This cross-sectional analysis of a prospective longitudinal database, NT Cancer Registry (1990–2017), includes all reported cases of GI (oesophagus, gastric, small intestinal, pancreas, colon, and rectum) adenocarcinomas. Poisson regression was used to estimate incidence ratio ratios, and survival was modelled using Cox proportional hazard models separately for people aged 18–50 years and >50 years. Results: A total of 1608 cases of GI adenocarcinoma were recorded during the time of the study. While the overall incidence in people 18–50 years remained unchanged over this time (p = 0.51), the rate in individuals aged >50 years decreased (IRR = 0.65 (95% CI 0.56–0.75; p < 0.0001)). Incidence rates were significantly less in females >50 years (IRR = 0.67 95% CI 0.59–0.75; p < 0.0001), and their survival was significantly better (HR = 0.84 (95%CI 0.72–0.98; p < 0.03)) compared to males. Overall survival across all GI subsites improved in both age cohorts, especially between 2010 and 2017 (HR = 0.45 (95%CI 0.29–0.72; p < 0.0007) and HR = 0.64 (95%CI 0.52–0.78; p < 0.0001), respectively) compared to 1990–1999, driven by an improvement in survival in colonic adenocarcinoma alone, as the survival remained unchanged in other GI subsites. The incidence was significantly lower in Indigenous patients compared to non-Indigenous patients, in both age cohorts (18–50 years IRR = 0.68 95% CI 0.51–0.91; p < 0.009 and >50 years IRR = 0.48 95% CI 0.40–0.57; p < 0.0001). However, Indigenous patients had worse survival rates (18–50 years HR = 2.06 95% CI 1.36–3.11; p < 0.0007 and >50 years HR = 1.66 95% CI 1.32–2.08; p < 0.0001). Conclusions: There is a trend towards an increased incidence of young-onset GI adenocarcinomas in the NT. Young Indigenous patients have lower incidence but worse survival across all GI subsites, highlighting significant health inequities in life expectancy. Targeted, culturally safe Indigenous community-focussed programs are needed for early detection and patient-centred management of GI adenocarcinomas.

20 April 2023 in Anz Journal of Surgery
Verified
Journal Article
Closed access
MSMia Shepherdson
Mia Shepherdson
DKDaniel Kilburn
Daniel Kilburn
SUShahid Ullah
Shahid Ullah
TPTimothy Price
Timothy Price
CKChristos S. Karapetis
Christos S. Karapetis
ARAmitesh C. Roy
Amitesh C. Roy

23 May 2024 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
MSMia Shepherdson
Mia Shepherdson
AKAshlee Koch
Ashlee Koch
WGWillem Gheysen
Willem Gheysen
EBElizabeth Beare
Elizabeth Beare
JAJan Ardui
Jan Ardui

4 March 2026 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MSMia Shepherdson
Mia Shepherdson
SESuzanne Edwards
Suzanne Edwards
MBMelissa Bochner
Melissa Bochner

11 June 2026 in Internal Medicine Journal
Verified
Journal Article
Open access
PDF file
CSCassidy M. Van Stiphout
Cassidy M. Van Stiphout
AMAbigail Miller
Abigail Miller
MSMia Shepherdson
Mia Shepherdson
TSTarik Sammour
Tarik Sammour
SVSina Vatandoust
Sina Vatandoust
ARAmitesh C. Roy
Amitesh C. Roy
Treatment of luminal gastrointestinal malignancies with curative intent has traditionally required a combination of systemic treatments and complex surgical resections, which carry risks to function and quality of life. Organ‐sparing approaches to treating gastrointestinal malignancies have advanced significantly. With increasing efficacy of upfront systemic and radiation therapies, select patients can safely avoid radical surgery while maintaining oncologic outcomes. This review discusses current and future organ‐sparing approaches in the management of gastro‐oesophageal, colon, rectal and anal cancers.